ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1554

Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Philip J Mease1, Chitra Karki2, Mei Liu2, YouFu Li3, Peter Hur4 and Jeffrey D. Greenberg5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5New York University School of Medicine, New York, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-TNF therapy, Biologics, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 6, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This study examined disease characteristics and described patterns of TNFi use through the first follow-up visit (≈ 6 months) in patients with PsA who initiated a first- vs second-line TNFi in the US Corrona PsA/SpA Registry.

Methods: This study included adult patients with PsA enrolled in the Corrona PsA/SpA Registry who initiated first- or second-line TNFi therapy between March 2013 and September 2016 with ≥ 1 follow-up visit. Patient demographics, disease characteristics and patient-reported outcomes were assessed at the time of TNFi initiation (baseline) and compared between cohorts using two-sample t-tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables. The proportions of patients who continued their index TNFi, discontinued without switching, or switched to another biologic at the time of the first follow-up visit was examined and compared between cohorts.

Results: Of the 230 patients with PsA who had ≥ 1 follow-up visit (median [IQR] time to first follow-up, 6.8 [6.0, 9.7] months), 139 patients initiated a first-line TNFi and 91 patients initiated a second-line TNFi. At baseline, patients who initiated a second-line TNFi had higher enthesitis and dactylitis counts, were less likely to be in minimal disease activity and had worse pain and fatigue compared with patients who initiated a first-line TNFi; however, these differences were not statistically significant (Table 1). A higher proportion of patients initiating a first-line TNFi continued their TNFi at the first follow-up visit than those initiating a second-line TNFi (76.3% vs 59.3%; P = 0.001). Among first-line initiators, 19.4% and 4.3% discontinued their index TNFi without switching, or switched to another biologic, respectively, compared with 22.0% and 18.7% of patients initiating a second-line TNFi (Figure 1; both P = 0.001). Of the 17 first- and 19 second-line TNFi initiators with provider-reported reasons for discontinuing or switching TNFis, the most common reasons were lack of effect (44.4% and 60.0%, respectively) and adverse effects (27.8% and 10.0%, respectively).

Conclusion: Patients with PsA initiating a second-line TNFi were more likely to discontinue or switch therapies compared with patients initiating a first-line TNFi, with the most common reason for discontinuation/switch due to lack of effect. These findings from a US registry suggest potential unmet needs for patients with PsA when using TNFis as a second-line therapy in a real-world setting.

 


Disclosure: P. J. Mease, Celgene, Novartis, AbbVie, Amgen, BMS, Lilly, Pfizer and UCB, 2,Celgene, Corrona, Novartis, AbbVie, Amgen, BMS, Crescendo, Genentech, Janssen, Lilly, Merck, Pfizer and UCB, 5,AbbVie, Amgen, BMS, Crescendo, Celgene, Genentech, Janssen, Pfizer and UCB, 8; C. Karki, Corrona, LLC, 3; M. Liu, Corrona, LLC, 3; Y. Li, University of Massachusetts Medical School, 3; P. Hur, Novartis Pharmaceuticals Corporation, 3; J. D. Greenberg, Corrona, LLC, 1,Corrona, LLC, 3,Eli Lilly, Genentech, Janssen, Novartis, Pfizer, 5.

To cite this abstract in AMA style:

Mease PJ, Karki C, Liu M, Li Y, Hur P, Greenberg JD. Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/discontinuation-and-switching-patterns-by-tnfi-line-of-therapy-in-patients-with-psoriatic-arthritis-results-from-the-corrona-psoriatic-arthritisspondyloarthritis-psaspa-registry/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discontinuation-and-switching-patterns-by-tnfi-line-of-therapy-in-patients-with-psoriatic-arthritis-results-from-the-corrona-psoriatic-arthritisspondyloarthritis-psaspa-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.